Hematopoietic stem cell transplantation for severe combined immunodeficiency

Area of Science:

• Immunology
• Pediatrics
• Genetics

Background:

• Severe combined immunodeficiency (SCID) presents as life-threatening infections in early infancy.
• It is a heterogeneous group of congenital diseases with varied clinical presentations and outcomes.
• Factors influencing outcomes include genetic defects, infections, maternal T cells, Omenn syndrome, and non-immunological symptoms.

Purpose of the Study:

• To review the disease-specific aspects of SCID.
• To discuss how these aspects influence therapeutic strategies for SCID.
• To highlight hematopoietic stem cell transplantation (HSCT) as the only curative option.

Main Methods:

• This review synthesizes current knowledge on SCID.
• It focuses on factors affecting clinical presentation and therapeutic outcomes.
• It examines the specific considerations for HSCT in SCID patients.

Main Results:

• SCID management is complex due to heterogeneous genetic defects and clinical variability.
• Infectious complications and immunological factors significantly impact patient outcomes.
• Hematopoietic stem cell transplantation (HSCT) is the established curative treatment for SCID.

Conclusions:

• HSCT is the sole curative approach for SCID, offering long-term disease resolution.
• Therapeutic goals for HSCT in SCID differ substantially from those in malignant or hematological diseases.
• Understanding SCID's unique characteristics is crucial for optimizing HSCT strategies and improving patient outcomes.